An earlier version of the drug, Ceredase, helped launch the lucrative market for high-priced orphan disease drugs, which is now one of the brightest spots in biotech.
FORBES: Pfizer Enters Market For Super-Expensive, Ultra-Rare Disease Drugs -- With A Price Cut